Research analysts at Piper Sandler initiated coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) in a report issued on Thursday, MarketBeat Ratings reports. The firm set an "overweight" rating and a $6.00 price target on the biotechnology company's stock. Piper Sandler's price target would indicate a potential upside of 280.95% from the stock's previous close.
A number of other research firms have also recently commented on ACRS. Scotiabank dropped their price objective on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a research report on Friday, May 9th. Wedbush reaffirmed an "outperform" rating and issued a $8.00 price objective on shares of Aclaris Therapeutics in a research report on Monday, June 23rd. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, June 25th. Finally, Cantor Fitzgerald began coverage on Aclaris Therapeutics in a research note on Tuesday, March 18th. They issued an "overweight" rating on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Aclaris Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $8.71.
Check Out Our Latest Analysis on ACRS
Aclaris Therapeutics Price Performance
Shares of ACRS stock traded down $0.02 during mid-day trading on Thursday, hitting $1.58. The stock had a trading volume of 429,541 shares, compared to its average volume of 1,200,088. Aclaris Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $5.17. The firm has a market cap of $170.54 million, a PE ratio of -1.13 and a beta of 0.38. The company's 50-day simple moving average is $1.41 and its 200-day simple moving average is $1.77.
Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 30.73% and a negative net margin of 732.42%. On average, analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current year.
Institutional Trading of Aclaris Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. ExodusPoint Capital Management LP acquired a new stake in Aclaris Therapeutics during the 4th quarter worth approximately $26,000. Invesco Ltd. acquired a new position in shares of Aclaris Therapeutics during the 4th quarter valued at $28,000. Graham Capital Management L.P. acquired a new position in shares of Aclaris Therapeutics during the 4th quarter valued at $35,000. Commonwealth Equity Services LLC acquired a new position in shares of Aclaris Therapeutics during the 4th quarter valued at $36,000. Finally, Alpine Global Management LLC purchased a new position in Aclaris Therapeutics in the fourth quarter valued at about $38,000. Institutional investors and hedge funds own 98.34% of the company's stock.
Aclaris Therapeutics Company Profile
(
Get Free Report)
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Read More
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
